BioSpace News Archive

Following last year’s stellar initial public offering in October, where it raised $80.5 million, about $10 million over initial expectations, LogicBio Therapeutics is planning a gene-editing clinical trial in children.

The U.S. Food and Drug Administration (FDA) and some biosimilar and generic drug advocates were concerned that the naming for biosimilars—the branded drug’s name and a unique, four-letter suffix—made the drugs sound inferior to consumers than their branded counterparts.

Continued good sales growth and strong operating profit

Technology innovators in super-resolution microscopy, Amsterdam-based Confocal.nl, are running workshops on Re-scan Confocal Microscopy with demonstrations to illustrate the use of use of the technique.

Data demonstrate platform feasibility to rapidly generate novel ADC combinations with superior stability

Aphria Inc. President, Jakob Ripshtein, is proposed to replace Mr Battersby as Non-Executive Director (pending ODC approval)

Karolinska Development’s portfolio company Forendo Pharma today announces positive results from a Phase Ia study with the drug candidate FOR 6219 for the treatment of endometriosis.

Martin Shkreli may be behind bars, but that doesn’t mean he does not take a direct hand in running Turing Pharmaceuticals, the company that has been redubbed Phoenixus AG. The WSJ reports that Shkreli is still very much involved in the leadership of the company he founded.

TherapeuticsMD, Inc. announced the schedule of oral presentations on clinical data for BIJUVATM and ANNOVERATM, and poster presentations related to menopause symptoms and treatments, at the International Society for the Study of Women’s Sexual Health and the International Society of Sexual Medicine joint annual meeting in Atlanta, GA on March 8-9, 2019.

Rafael Holdings, Inc., has scheduled its report of financial and operational results covering the second quarter of its 2019 fiscal year for Tuesday, March 12, 2019.